IGF-1 DES (1mg)

What is IGF-1 DES (1mg)?

IGF-1 DES (1 mg) is a recombinant peptide analog classified under muscle and growth factor research peptides. It is a truncated variant of human insulin-like growth factor-1 (IGF-1), lacking the first three N-terminal amino acids of the native IGF-1 molecule. This structural modification distinguishes it from full-length IGF-1 and makes it particularly useful in receptor-focused and cell-based experimental systems.

In research settings, IGF-1 DES is widely studied for its interaction with the IGF-1 receptor (IGF-1R), a transmembrane receptor that regulates cellular growth, differentiation, metabolism, and survival signaling.

Because of its modified structure, IGF-1 DES is often used in experimental models to examine localized growth factor signaling, cell proliferation dynamics, protein synthesis pathways, and tissue-specific responses. Its defined molecular profile supports reproducibility and controlled observation in both in vitro and preclinical research frameworks.

This compound is not approved for therapeutic or diagnostic use and is strictly limited to controlled laboratory environments.

Product Specifications

• CAS Number: 112603-35-7
• Peptide Sequence:
  H-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala-OH
• Molecular Formula: C₃₁₉H₅₀₁N₉₁O₉₆S₇
• Molecular weight: 7371.48 g/mol
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 1 mg lyophilized powder in sealed research-grade vial
• Storage Conditions: Store at −20°C; protect from light and moisture
• Intended Use: For Laboratory Research Use Only

Key Characteristics of IGF-1 DES (1mg)

• Recombinant truncated analog of human IGF-1 (Des 1–3 variant).
• Engineered for controlled receptor-binding and signaling studies.
• High molecular weight peptide with a defined amino acid sequence and primary structure.
• Supplied as a lyophilized powder suitable for storage and handling in research settings.
• Verified using analytical methods such as HPLC and mass spectrometry.
• Suitable for cellular assays, receptor-binding studies, and mechanistic research.
• Designed for use in strictly controlled in vitro and preclinical models.
• Requires low-temperature storage to maintain structural integrity.

How IGF-1 DES (1mg) Supports Research

IGF-1 DES (1 mg) is used in laboratory investigations to study insulin-like growth factor signaling pathways and receptor-mediated cellular responses. Researchers use this truncated analog to examine how structural changes in growth factors influence receptor activation, intracellular signaling cascades, and downstream protein expression.

Because IGF-1 DES exhibits altered binding characteristics compared with full-length IGF-1, it is frequently incorporated into comparative studies assessing receptor affinity, signal duration, and localized cellular responses. It is commonly evaluated in models investigating myocyte activity, fibroblast proliferation, metabolic regulation, and tissue remodeling processes. Its consistent composition allows investigators to analyze growth factor–related mechanisms under standardized experimental conditions.

Typical experimental applications include receptor-binding studies, protein synthesis assays, and analyses of signaling pathway activation in response to IGF-1 DES treatment. All research applications remain investigational and confined to controlled laboratory environments.

Research Applications & Usage Information

IGF-1 DES (1 mg) is commonly utilized in laboratory research for:

• IGF-1 receptor binding and activation studies
• Cellular proliferation and differentiation assays
• Protein synthesis and intracellular signaling pathway analysis
• Muscle cell (myoblast/myocyte) culture research
• Tissue regeneration and repair models in preclinical systems
• Comparative evaluation of full-length IGF-1 versus truncated analogs
• Endocrine and metabolic pathway investigations

All applications remain investigational and are restricted to controlled laboratory environments.

Handling and Storage Recommendations

To maintain structural integrity and experimental reliability:

• Store unopened vials at −20°C in a dry, light-protected environment.
• Minimize exposure to elevated temperatures prior to reconstitution.
• Allow the vial to equilibrate to room temperature before opening to minimize condensation.
• Reconstitute under sterile laboratory conditions using an appropriate diluent.
• After reconstitution, store at 2–8 °C and use within protocol‑defined laboratory timeframes.
• Avoid repeated freeze–thaw cycles to preserve peptide stability.
• Dispose of materials according to institutional laboratory safety protocols.

Proper storage and careful handling help maintain peptide integrity and ensure reliable experimental outcomes.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996;28(10):1085-1087. doi:10.1016/1357-2725(96)00056-8
2. Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. 1988;251(1):95-103. doi:10.1042/bj2510095
3. McKinnon P, Ross M, Wells JR, Ballard FJ, Francis GL. Expression, purification and characterization of secreted recombinant human insulin-like growth factor-I (IGF-I) and the potent variant des(1-3) IGF-I in Chinese hamster ovary cells. J Mol Endocrinol. 1991;6(3):231-239. doi:10.1677/jme.0.0060231